EVOQ
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
CIRP Admission
Evoq Remedies Ltd has been admitted into corporate insolvency resolution process by the National Company Law Tribunal, Ahmedabad, on June 9, 2026, following a petition filed by operational creditor Harbhole Agrotech under Section 9 of the Insolvency and Bankruptcy Code. The claim arose from an unpaid advance of ₹1.95 crore paid by Harbhole Agrotech for supply of FSG Castor Oil, which was neither delivered nor refunded after the default date of September 1, 2025. The tribunal declared a moratorium under Section 14 and appointed Ms. Dipti Narayan Mundra as interim resolution professional. Evoq Remedies had earlier reported severe financial distress, including a going-concern qualification in its audited results, near-complete cessation of business, unpaid statutory dues of ₹100 lakhs, and an active SEBI investigation. The company's market capitalisation is approximately ₹7 crores.
Powered by Tijori
Evoq Remedies Ltd has been admitted into corporate insolvency resolution process by the National Company Law Tribunal, Ahmedabad, on June 9, 2026, following a petition filed by operational creditor Harbhole Agrotech under Section 9 of the Insolvency and Bankruptcy Code. The claim arose from an unpaid advance of ₹1.95 crore paid by Harbhole Agrotech for supply of FSG Castor Oil, which was neither delivered nor refunded after the default date of September 1, 2025. The tribunal declared a moratorium under Section 14 and appointed Ms. Dipti Narayan Mundra as interim resolution professional. Evoq Remedies had earlier reported severe financial distress, including a going-concern qualification in its audited results, near-complete cessation of business, unpaid statutory dues of ₹100 lakhs, and an active SEBI investigation. The company's market capitalisation is approximately ₹7 crores.
Powered by Tijori
Insolvency Filing
Evoq Remedies Ltd disclosed that operational creditor Harbhole Agrotech filed an application under Section 9 of the Insolvency and Bankruptcy Code before the National Company Law Tribunal in Ahmedabad on 20th April 2026, seeking to initiate a corporate insolvency resolution process against the company. The company made the intimation public on 10th June 2026. Evoq Remedies had previously reported severe financial distress, including a going-concern qualification in its audited annual results for FY2026, near-complete cessation of business, unpaid income tax and TDS totalling ₹100 lakhs, unconfirmed related party loans of ₹670 lakhs, and an active SEBI investigation. The company's market capitalisation stands at approximately ₹7 crores.
Powered by Tijori
Evoq Remedies Ltd disclosed that operational creditor Harbhole Agrotech filed an application under Section 9 of the Insolvency and Bankruptcy Code before the National Company Law Tribunal in Ahmedabad on 20th April 2026, seeking to initiate a corporate insolvency resolution process against the company. The company made the intimation public on 10th June 2026. Evoq Remedies had previously reported severe financial distress, including a going-concern qualification in its audited annual results for FY2026, near-complete cessation of business, unpaid income tax and TDS totalling ₹100 lakhs, unconfirmed related party loans of ₹670 lakhs, and an active SEBI investigation. The company's market capitalisation stands at approximately ₹7 crores.
Powered by Tijori
Evoq Remedies Board Withdraws Proposals To Issue Preferential Shares
Aug 21 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
BOARD WITHDRAWS PROPOSALS TO ISSUE PREFERENTIAL SHARES
Source text: [ID:]
Further company coverage: EVOQ.BO
(([email protected];))
Aug 21 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
BOARD WITHDRAWS PROPOSALS TO ISSUE PREFERENTIAL SHARES
Source text: [ID:]
Further company coverage: EVOQ.BO
(([email protected];))
Evoq Remedies To Discuss Fund Raising Via Equity Shares/Warrants
April 24 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
TO DISCUSS FUND RAISING VIA EQUITY SHARES/WARRANTS
Source text: ID:nBSEcgpWlm
Further company coverage: EVOQ.BO
(([email protected];;))
April 24 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
TO DISCUSS FUND RAISING VIA EQUITY SHARES/WARRANTS
Source text: ID:nBSEcgpWlm
Further company coverage: EVOQ.BO
(([email protected];;))
Evoq Remedies To Consider Fund Raising
April 3 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
EVOQ REMEDIES - TO CONSIDER FUND RAISING
Source text: ID:nBSEbCR5xr
Further company coverage: EVOQ.BO
(([email protected];))
April 3 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
EVOQ REMEDIES - TO CONSIDER FUND RAISING
Source text: ID:nBSEbCR5xr
Further company coverage: EVOQ.BO
(([email protected];))
Evoq Remedies Gets Show Cause Notice From SEBI
Dec 16 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
EVOQ REMEDIES LTD - RECEIVES SHOW CAUSE NOTICE FROM SEBI
EVOQ REMEDIES LTD - NO PENALTIES OR FINES LEVIED IN SHOW CAUSE NOTICE
Source text: ID:nBSE6KWgDd
Further company coverage: EVOQ.BO
(([email protected];))
Dec 16 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
EVOQ REMEDIES LTD - RECEIVES SHOW CAUSE NOTICE FROM SEBI
EVOQ REMEDIES LTD - NO PENALTIES OR FINES LEVIED IN SHOW CAUSE NOTICE
Source text: ID:nBSE6KWgDd
Further company coverage: EVOQ.BO
(([email protected];))
Evoq Remedies Appoints Bhumishth Narendrabhai Patel As MD
Aug 1 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
APPOINTS BHUMISHTH NARENDRABHAI PATEL AS MD
MD PAYAL BHUMISHTH PATEL RESIGNS
Source text for Eikon: ID:nBSE50cY3B
Further company coverage: EVOQ.BO
(([email protected];))
Aug 1 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
APPOINTS BHUMISHTH NARENDRABHAI PATEL AS MD
MD PAYAL BHUMISHTH PATEL RESIGNS
Source text for Eikon: ID:nBSE50cY3B
Further company coverage: EVOQ.BO
(([email protected];))
Evoq Remedies Approved Fund Raise Up To 226 Million Rupees
Jan 22 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
APPROVED FUND RAISE UP TO 226 MILLION RUPEES BY WAY OF ISSUE OF SHARES
FUND RAISE THROUGH PREFERENTIAL ALLOTMENT TO PERSON(S)/ ENTITY(IES) OF NON- PROMOTER CATEGORY
Further company coverage: EVOQ.BO
(([email protected];))
Jan 22 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
APPROVED FUND RAISE UP TO 226 MILLION RUPEES BY WAY OF ISSUE OF SHARES
FUND RAISE THROUGH PREFERENTIAL ALLOTMENT TO PERSON(S)/ ENTITY(IES) OF NON- PROMOTER CATEGORY
Further company coverage: EVOQ.BO
(([email protected];))
Evoq Remedies Gets Order Worth 1.36 Billion Rupees
Jan 10 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
GETS ORDER WORTH 1.36 BILLION RUPEES
Source text for Eikon: ID:nBSE40SGly
Further company coverage: EVOQ.BO
(([email protected];))
Jan 10 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
GETS ORDER WORTH 1.36 BILLION RUPEES
Source text for Eikon: ID:nBSE40SGly
Further company coverage: EVOQ.BO
(([email protected];))
Evoq Remedies Ltd- Resignation Of Dahyabhai Patel As MD
Evoq Remedies Ltd EVOQ.BO:
EVOQ REMEDIES LTD- RESIGNATION OF DAHYABHAI PATEL AS MD
EVOQ REMEDIES LTD- APPOINTMENT OF BHUMISHTH PATEL AS MD
Source text for Eikon: ID:nBSE2WR2vh
Further company coverage: EVOQ.BO
Evoq Remedies Ltd EVOQ.BO:
EVOQ REMEDIES LTD- RESIGNATION OF DAHYABHAI PATEL AS MD
EVOQ REMEDIES LTD- APPOINTMENT OF BHUMISHTH PATEL AS MD
Source text for Eikon: ID:nBSE2WR2vh
Further company coverage: EVOQ.BO
Evoq Remedies Appoints Dahyabhai Patel As MD
May 25 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
EVOQ REMEDIES LTD - APPOINTS DAHYABHAI PATEL AS MD
Source text for Eikon: ID:nBSE8GZpQV
Further company coverage: EVOQ.BO
(([email protected];))
May 25 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
EVOQ REMEDIES LTD - APPOINTS DAHYABHAI PATEL AS MD
Source text for Eikon: ID:nBSE8GZpQV
Further company coverage: EVOQ.BO
(([email protected];))
Evoq Remedies Says Bhumishth Patel Resigns As MD
March 31 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
BHUMISHTH PATEL RESIGNS AS MD
Source text for Eikon: ID:nBSE4tGmdb
Further company coverage: EVOQ.BO
(([email protected];))
March 31 (Reuters) - Evoq Remedies Ltd EVOQ.BO:
BHUMISHTH PATEL RESIGNS AS MD
Source text for Eikon: ID:nBSE4tGmdb
Further company coverage: EVOQ.BO
(([email protected];))
Events:
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does EVOQ Remedies do?
EVOQ Remedies Ltd. specializes in providing Pharmaceuticals Raw Material products, Excipients, and Bulk Drugs with a team of industry experts ensuring quality and affordability through certified manufacturers and importers.
Who are the competitors of EVOQ Remedies?
EVOQ Remedies major competitors are Dipna Pharma., JFL Life Sciences, Deccan Health Care, Vivimed Labs, Biofil Chem & Pharma, Bharat Immunological, Makers Laboratories. Market Cap of EVOQ Remedies is ₹6 Crs. While the median market cap of its peers are ₹52 Crs.
Is EVOQ Remedies financially stable compared to its competitors?
EVOQ Remedies seems to be less financially stable compared to its competitors. Altman Z score of EVOQ Remedies is 2.35 and is ranked 5 out of its 8 competitors.
Does EVOQ Remedies pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. EVOQ Remedies latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has EVOQ Remedies allocated its funds?
Companies resources are allocated to majorly unproductive assets like Accounts Receivable, Short Term Loans & Advances
How strong is EVOQ Remedies balance sheet?
Balance sheet of EVOQ Remedies is moderately strong.
Is the profitablity of EVOQ Remedies improving?
No, profit is decreasing. The profit of EVOQ Remedies is ₹0.09 Crs for Mar 2025, ₹0.45 Crs for Mar 2024 and ₹1.62 Crs for Mar 2023
Is the debt of EVOQ Remedies increasing or decreasing?
Yes, The net debt of EVOQ Remedies is increasing. Latest net debt of EVOQ Remedies is ₹0.07 Crs as of Mar-26. This is greater than Mar-25 when it was -₹0.23 Crs.
Is EVOQ Remedies stock expensive?
EVOQ Remedies is not expensive. Latest PE of EVOQ Remedies is 0, while 3 year average PE is 46.49. Also latest EV/EBITDA of EVOQ Remedies is 0 while 3yr average is 4.79.
Has the share price of EVOQ Remedies grown faster than its competition?
EVOQ Remedies has given lower returns compared to its competitors. EVOQ Remedies has grown at ~-46.29% over the last 3yrs while peers have grown at a median rate of -9.26%
Is the promoter bullish about EVOQ Remedies?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in EVOQ Remedies is 0.02% and last quarter promoter holding is 11.21%
Are mutual funds buying/selling EVOQ Remedies?
There is Insufficient data to gauge this.